Dabigatran etexilate STADA Nordic: Uses, Dosage & Side Effects
A direct oral anticoagulant (DOAC) containing dabigatran etexilate, used to prevent stroke in atrial fibrillation and to treat and prevent venous thromboembolism
Dabigatran etexilate STADA Nordic is a direct oral anticoagulant (DOAC) that contains the active substance dabigatran etexilate. It belongs to a class of medications known as direct thrombin inhibitors, which work by blocking thrombin – a key enzyme in the blood clotting cascade – to prevent the formation of blood clots. Dabigatran etexilate STADA Nordic is available as 75 mg hard capsules and is prescribed for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), and the prevention of venous thromboembolism after elective hip or knee replacement surgery. This medication requires a prescription and should only be used under medical supervision.
Quick Facts: Dabigatran etexilate STADA Nordic
Key Takeaways
- Dabigatran etexilate STADA Nordic is a direct oral anticoagulant (DOAC) that directly inhibits thrombin, preventing blood clot formation. It is used for stroke prevention in atrial fibrillation and for treating venous thromboembolism.
- Unlike warfarin, dabigatran does not require routine blood monitoring (INR tests), has a rapid onset of action within 1–2 hours, and has a specific reversal agent (idarucizumab/Praxbind) available for emergency situations.
- The most important risk with dabigatran is bleeding. Patients should report any unusual bruising, prolonged bleeding, blood in urine or stool, or unexplained fatigue to their doctor immediately.
- Kidney function must be assessed before starting treatment and monitored regularly, as approximately 80% of dabigatran is eliminated through the kidneys. Dose adjustments are required in patients with moderate renal impairment.
- Capsules must be swallowed whole – never opened, crushed, or chewed – as this dramatically increases drug absorption and the risk of serious bleeding complications.
What Is Dabigatran etexilate STADA Nordic and What Is It Used For?
Dabigatran etexilate STADA Nordic contains the active substance dabigatran etexilate, which is a prodrug – meaning it is converted into its active form, dabigatran, after being absorbed in the body. Dabigatran belongs to a class of anticoagulant medications known as direct thrombin inhibitors (DTIs), and more broadly to the group of direct oral anticoagulants (DOACs), sometimes also referred to as novel oral anticoagulants (NOACs). These medications represent a significant advancement over traditional anticoagulants such as warfarin, offering more predictable pharmacokinetics, fewer drug and food interactions, and the elimination of the need for routine blood monitoring.
The coagulation cascade is a complex series of enzymatic reactions that ultimately leads to the formation of a blood clot (thrombus). Thrombin (Factor IIa) plays a central role in this process: it converts soluble fibrinogen into insoluble fibrin strands, activates platelets, and amplifies the coagulation cascade through positive feedback mechanisms. By directly binding to and inhibiting the active site of thrombin – both free thrombin circulating in the blood and thrombin that is already bound to a forming clot – dabigatran effectively prevents the conversion of fibrinogen to fibrin and disrupts the clotting process. This dual inhibition of free and clot-bound thrombin distinguishes dabigatran from indirect thrombin inhibitors such as heparin.
After oral administration, dabigatran etexilate is rapidly absorbed from the gastrointestinal tract and converted to dabigatran by esterase-mediated hydrolysis in the plasma and the liver. Peak plasma concentrations are typically reached within 0.5 to 2 hours after ingestion. The bioavailability of the intact capsule is approximately 6.5%, which is by design – the prodrug formulation is necessary because dabigatran itself has very poor oral absorption. The terminal elimination half-life of dabigatran is approximately 12 to 17 hours in healthy subjects with normal kidney function, which supports twice-daily dosing for most indications. Notably, approximately 80% of dabigatran is excreted unchanged by the kidneys, making renal function a critical factor in dosing decisions.
Dabigatran etexilate STADA Nordic is a generic formulation of dabigatran etexilate that has been demonstrated to be bioequivalent to the originator product. It is approved for the following indications based on the established efficacy and safety profile of dabigatran etexilate:
- Prevention of stroke and systemic embolism in atrial fibrillation: Dabigatran is used in adult patients with non-valvular atrial fibrillation (AF) who have one or more risk factors for stroke, such as prior stroke or transient ischemic attack, age 75 years or older, heart failure, diabetes mellitus, or hypertension. The landmark RE-LY trial, published in the New England Journal of Medicine in 2009, demonstrated that dabigatran 150 mg twice daily was superior to warfarin in preventing stroke and systemic embolism, while dabigatran 110 mg twice daily was non-inferior to warfarin with a significantly lower rate of major bleeding.
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE): After initial treatment with a parenteral anticoagulant for at least 5 days, dabigatran can be used for the ongoing treatment of DVT and PE in adults. The RE-COVER and RE-COVER II trials showed that dabigatran was non-inferior to warfarin for the treatment of acute venous thromboembolism, with a comparable safety profile.
- Prevention of recurrent DVT and PE: Following initial treatment of venous thromboembolism, dabigatran is used to reduce the risk of recurrence. The RE-MEDY and RE-SONATE trials demonstrated that extended dabigatran therapy was effective in preventing recurrent venous thromboembolism.
- Prevention of venous thromboembolism after elective hip or knee replacement surgery: Dabigatran is used to prevent blood clots in the legs and lungs following major orthopedic surgery. The RE-MODEL, RE-NOVATE, and RE-MOBILIZE trials established the efficacy and safety of dabigatran for thromboprophylaxis in these surgical settings.
Unlike warfarin, which works by inhibiting the synthesis of vitamin K-dependent clotting factors and requires regular INR blood monitoring, dabigatran directly targets a single enzyme (thrombin) in the clotting cascade. This means dabigatran has a more predictable anticoagulant effect, does not require routine blood testing, has far fewer dietary restrictions, and reaches therapeutic levels within hours rather than days. Furthermore, a specific reversal agent (idarucizumab) is available for dabigatran, allowing rapid neutralization of its anticoagulant effect in emergency situations.
The 75 mg strength of Dabigatran etexilate STADA Nordic is primarily used in specific clinical scenarios where lower dosing is required – for example, in combination with other capsule strengths to achieve the recommended total dose, or in certain patient populations such as those with moderate renal impairment or those co-prescribed verapamil. Your prescribing physician will determine the appropriate dose based on your individual clinical situation, kidney function, age, and concomitant medications.
What Should You Know Before Taking Dabigatran etexilate STADA Nordic?
Contraindications
There are several situations in which dabigatran etexilate must not be used. Understanding these absolute contraindications is essential for patient safety, as the consequences of inappropriate use can be severe or life-threatening.
- Hypersensitivity: Do not take dabigatran if you are allergic to dabigatran etexilate or any of the other ingredients, including tartaric acid, acacia, hypromellose, dimethicone, talc, or hydroxypropylcellulose.
- Severe renal impairment: Dabigatran must not be used in patients with a creatinine clearance (CrCl) below 30 mL/min, as the drug is predominantly cleared by the kidneys and severe renal impairment leads to excessive accumulation and a markedly increased bleeding risk.
- Active clinically significant bleeding: Do not use dabigatran if you currently have active bleeding that is clinically significant, including but not limited to gastrointestinal hemorrhage, intracranial bleeding, or any other source of ongoing significant blood loss.
- Lesions or conditions at significant risk of major bleeding: This includes current or recent gastrointestinal ulceration, malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal, or ophthalmic surgery, recent intracranial hemorrhage, known or suspected esophageal varices, arteriovenous malformations, vascular aneurysms, or major intraspinal or intracerebral vascular abnormalities.
- Concurrent treatment with other anticoagulants: Dabigatran should not be used simultaneously with unfractionated heparin (except for maintaining venous catheter patency), low molecular weight heparin, fondaparinux, warfarin, or other oral anticoagulants, as this dramatically increases the risk of bleeding.
- Hepatic impairment or liver disease expected to impact survival: Dabigatran is contraindicated in patients with significant liver disease that is expected to affect survival, as altered liver function may affect the conversion of the prodrug to active dabigatran.
- Treatment with systemic ketoconazole, cyclosporine, itraconazole, dronedarone, or glecaprevir/pibrentasvir: These drugs are potent P-glycoprotein (P-gp) inhibitors and significantly increase dabigatran plasma concentrations, leading to an unacceptable bleeding risk.
- Prosthetic heart valves requiring anticoagulant treatment: Dabigatran must not be used in patients with mechanical heart valves. The RE-ALIGN trial was terminated early due to an excess of thromboembolic events and bleeding in patients with mechanical heart valves treated with dabigatran compared to warfarin.
Dabigatran must NEVER be used in patients with mechanical (prosthetic) heart valves. The RE-ALIGN clinical trial demonstrated that dabigatran was associated with significantly more thromboembolic complications (stroke, heart attack, clot on the valve) and more bleeding compared to warfarin in this patient population. The trial was stopped early due to safety concerns. Patients with mechanical heart valves must continue to use warfarin or another vitamin K antagonist.
Warnings and Precautions
Before and during treatment with dabigatran, several important precautions must be carefully considered. Discuss the following with your doctor before starting this medication:
- Bleeding risk: The most significant risk with dabigatran, as with all anticoagulants, is bleeding. While it prevents harmful blood clots, it also impairs the body's normal ability to stop bleeding. You should seek immediate medical attention if you experience unexpected bleeding, bleeding that takes a long time to stop, unusual bruising, blood in your urine (pink or red urine), blood in your stools (black, tarry stool or red blood), bleeding from the gums, nosebleeds that are difficult to control, unexplained tiredness or shortness of breath, or vomiting blood or material that looks like coffee grounds.
- Renal function monitoring: Because approximately 80% of dabigatran is excreted by the kidneys, renal function must be assessed before starting treatment using the Cockcroft-Gault formula. Kidney function should be monitored at least once yearly in all patients, and more frequently (every 3–6 months) in patients with a CrCl of 30–50 mL/min, patients over 75 years, or those with conditions that may impair kidney function over time.
- Age-related considerations: Patients aged 80 years and older have an increased risk of bleeding with dabigatran due to age-related decline in kidney function and other factors. Dose reduction may be recommended for elderly patients.
- Surgery and invasive procedures: Dabigatran must be temporarily discontinued before surgical or invasive procedures to reduce the risk of excessive bleeding. The duration of discontinuation depends on kidney function and the bleeding risk of the procedure. For procedures with a standard risk of bleeding, dabigatran should generally be stopped at least 24 hours before the procedure. For major surgery or procedures with a high bleeding risk, discontinuation at least 48 hours before is recommended. In patients with renal impairment, longer discontinuation periods are necessary.
- Spinal/epidural anesthesia or puncture: There is a risk of spinal or epidural hematoma (blood collection around the spinal cord) when neuraxial anesthesia is performed in patients receiving anticoagulants. This can lead to long-term or permanent paralysis. Specific timing guidelines must be followed for the last dose of dabigatran before catheter placement and for the first dose after catheter removal.
- Gastrointestinal effects: Dabigatran has been associated with a higher rate of gastrointestinal bleeding compared to warfarin, particularly in patients aged 75 and older. Gastrointestinal symptoms such as dyspepsia, gastritis-like symptoms, and epigastric pain have also been reported. Taking dabigatran with food or a proton pump inhibitor may help reduce these symptoms.
- Low body weight: There is limited clinical data for patients weighing less than 50 kg. These patients may have increased exposure to dabigatran and should be closely monitored.
- Discontinuation risks: Do not stop taking dabigatran without consulting your doctor. Premature discontinuation of anticoagulation in patients with atrial fibrillation increases the risk of stroke. If dabigatran must be stopped for reasons other than pathological bleeding or completion of therapy, consider covering with another anticoagulant.
Pregnancy and Breastfeeding
There is very limited data on the use of dabigatran in pregnant women. Animal studies have shown reproductive toxicity, including decreased fetal body weight and increased fetal variation at doses that produced higher plasma levels than those seen in clinical practice. The potential risk to human pregnancy is unknown. As a precaution, dabigatran should not be used during pregnancy unless clearly necessary and only if the expected benefit outweighs the potential risk to the fetus. Women of childbearing potential should use effective contraception to avoid pregnancy during treatment.
It is not known whether dabigatran or its metabolites are excreted in human breast milk. No clinical data on the effect of dabigatran on breastfed infants are available. Breastfeeding should be discontinued during treatment with dabigatran. A decision must be made whether to discontinue breastfeeding or to discontinue/abstain from dabigatran therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
There are no human data on the effect of dabigatran on male or female fertility. In preclinical studies, no effect on female fertility was observed. In male animals, a decrease in implantations and an increase in pre-implantation loss were noted at doses producing plasma levels approximately 5 to 10 times higher than those achieved in patients.
Driving and Operating Machinery
Dabigatran etexilate STADA Nordic has no known effect on the ability to drive and use machines. However, if you experience side effects such as dizziness during treatment, you should exercise caution when driving or operating machinery. Discuss with your doctor if you have any concerns about your ability to perform these activities safely.
How Does Dabigatran etexilate STADA Nordic Interact with Other Drugs?
Unlike many other medications, dabigatran is not metabolized by the cytochrome P450 (CYP) enzyme system, which means it has relatively few metabolic drug interactions. However, dabigatran etexilate (the prodrug) is a substrate of the P-glycoprotein (P-gp) efflux transporter, which plays a critical role in determining how much of the drug is absorbed from the gut and how it is distributed in the body. Therefore, the most clinically significant drug interactions with dabigatran involve P-gp inhibitors (which increase dabigatran levels) and P-gp inducers (which decrease dabigatran levels). In addition, any drug that affects hemostasis – including other anticoagulants, antiplatelet agents, and nonsteroidal anti-inflammatory drugs (NSAIDs) – can pharmacodynamically increase the risk of bleeding when combined with dabigatran.
The absorption of dabigatran etexilate depends significantly on the acidic environment of the stomach. The capsule contains tartaric acid pellets to ensure adequate local acidity for optimal absorption. Proton pump inhibitors (PPIs), H2-receptor antagonists, and antacids can raise gastric pH and slightly reduce dabigatran absorption, but this reduction (approximately 10–30%) is generally not considered clinically significant, and dose adjustment is not required.
Major Interactions
| Interacting Drug | Mechanism | Clinical Significance |
|---|---|---|
| Ketoconazole (systemic) | Strong P-gp inhibitor; increases dabigatran AUC by ~150% | Contraindicated – must not be combined |
| Dronedarone | Strong P-gp inhibitor; markedly increases dabigatran exposure | Contraindicated – must not be combined |
| Itraconazole | Strong P-gp inhibitor; significantly increases dabigatran levels | Contraindicated – must not be combined |
| Cyclosporine | Strong P-gp inhibitor; increases dabigatran exposure | Contraindicated – must not be combined |
| Glecaprevir/Pibrentasvir | P-gp inhibitor; increases dabigatran exposure | Contraindicated – must not be combined |
| Rifampicin | Strong P-gp inducer; reduces dabigatran AUC by ~65% | Avoid concomitant use – may render dabigatran ineffective |
| Warfarin and other anticoagulants | Additive anticoagulant effect | Contraindicated – excessive bleeding risk |
Moderate Interactions Requiring Caution
| Interacting Drug | Mechanism | Recommendation |
|---|---|---|
| Verapamil | Moderate P-gp inhibitor; increases dabigatran AUC by ~12–180% depending on timing and formulation | Dose reduction required; take dabigatran at least 2 hours before verapamil |
| Amiodarone | P-gp inhibitor; increases dabigatran AUC by ~12–60% | Dose reduction may be considered in patients at higher risk of bleeding |
| Quinidine | P-gp inhibitor; increases dabigatran levels | Use with caution; monitor for signs of bleeding |
| Aspirin (acetylsalicylic acid) | Pharmacodynamic interaction; inhibits platelet function | Increases bleeding risk; use only if clinically necessary with close monitoring |
| Clopidogrel and other P2Y12 inhibitors | Pharmacodynamic interaction; inhibits platelet aggregation | Significantly increases bleeding risk; careful benefit-risk assessment needed |
| NSAIDs (ibuprofen, naproxen, diclofenac) | Pharmacodynamic; impair hemostasis and may cause GI mucosal damage | Avoid if possible; short-acting NSAIDs preferred if needed; monitor for GI bleeding |
| SSRIs/SNRIs (fluoxetine, venlafaxine) | Pharmacodynamic; impair platelet function via serotonin depletion | May increase bleeding risk; monitor patients |
| Carbamazepine, Phenytoin | P-gp inducers; may reduce dabigatran levels | Avoid concomitant use if possible; may reduce anticoagulant efficacy |
| St John’s Wort (Hypericum perforatum) | P-gp inducer; reduces dabigatran absorption | Avoid concomitant use |
Tell your doctor, dentist, and pharmacist about all medications you are taking, including prescription drugs, over-the-counter medications, vitamins, and herbal supplements. This is especially important before any surgical, dental, or medical procedure, as dabigatran may need to be temporarily stopped to reduce bleeding risk.
What Is the Correct Dosage of Dabigatran etexilate STADA Nordic?
The dosage of dabigatran etexilate varies according to the clinical indication, the patient's age, kidney function, body weight, and concurrent medications. Dabigatran etexilate STADA Nordic 75 mg capsules are typically used in combination with other capsule strengths (such as 110 mg capsules) to achieve the prescribed total dose, or they may be used as the primary strength in specific dosing regimens. Always take exactly the dose prescribed by your doctor. Do not change your dose without medical advice.
Adults – Stroke Prevention in Atrial Fibrillation
Standard Dose
150 mg twice daily (one 150 mg capsule morning and evening), taken approximately 12 hours apart. This dose was shown to be superior to warfarin for stroke prevention in the RE-LY trial.
Reduced Dose – Elderly Patients
110 mg twice daily for patients aged 80 years or older, as this population has an increased bleeding risk. Physicians may also consider 110 mg twice daily for patients aged 75–80 years with additional bleeding risk factors.
Reduced Dose – Renal Impairment
110 mg twice daily should be considered for patients with moderate renal impairment (CrCl 30–50 mL/min), particularly if they have additional bleeding risk factors. Dabigatran is contraindicated if CrCl < 30 mL/min.
Dose Modification – Verapamil Co-administration
110 mg twice daily for patients co-prescribed verapamil. Dabigatran should be taken at least 2 hours before the verapamil dose to minimize the interaction.
Adults – Treatment and Prevention of DVT/PE
After Initial Parenteral Anticoagulation
150 mg twice daily, initiated after at least 5 days of treatment with a parenteral anticoagulant (such as low molecular weight heparin). Dose may be reduced to 110 mg twice daily in patients aged 80 or older, or those co-treated with verapamil.
Adults – VTE Prophylaxis After Elective Surgery
Hip Replacement Surgery
220 mg once daily (two 110 mg capsules), starting with 110 mg within 1–4 hours after surgery completion, then 220 mg once daily for 28–35 days total. Reduced to 150 mg once daily in patients aged 75 or older, those with moderate renal impairment, or those co-treated with verapamil.
Knee Replacement Surgery
220 mg once daily, starting with 110 mg within 1–4 hours after surgery, then 220 mg once daily for 10 days total. Reduced to 150 mg once daily in the same special populations as hip replacement.
Children and Adolescents
The safety and efficacy of dabigatran etexilate in children and adolescents under 18 years of age have not been established for the indications covered by Dabigatran etexilate STADA Nordic 75 mg capsules. There is currently no data available for this age group. Use in pediatric patients is therefore not recommended outside of specialized clinical settings and protocols.
Elderly Patients
Elderly patients require special attention when being prescribed dabigatran. Patients aged 75–80 years should be carefully assessed for bleeding risk, and a dose of 110 mg twice daily (for AF or VTE treatment) or 150 mg once daily (for surgical prophylaxis) should be considered. For patients aged 80 years and older, the recommended dose for AF stroke prevention is 110 mg twice daily. For all elderly patients, kidney function should be monitored at least annually, and more frequently if clinical circumstances suggest potential renal deterioration (dehydration, acute illness, addition of nephrotoxic medications).
Missed Dose
If you miss a dose of dabigatran, take it as soon as you remember, provided there are still at least 6 hours until the next scheduled dose. If fewer than 6 hours remain before the next dose, skip the missed dose entirely and take the next dose at the usual time. Do not take a double dose to make up for a missed one. Consistency in taking dabigatran at approximately the same times each day is important for maintaining stable anticoagulation.
Overdose
There is no specific antidote for dabigatran that can be administered at home. In the event of a suspected overdose, seek medical attention immediately. In a hospital setting, management of dabigatran overdose includes:
- Idarucizumab (Praxbind): This is a specific reversal agent for dabigatran. It is a humanized monoclonal antibody fragment that binds to dabigatran with extremely high affinity (approximately 350 times stronger than dabigatran's binding to thrombin), effectively neutralizing its anticoagulant effect within minutes. The approved dose is 5 g (two vials of 2.5 g/50 mL) administered as two consecutive intravenous infusions or as a bolus injection.
- Activated charcoal: If ingestion was recent (within 2 hours), oral activated charcoal may reduce absorption of dabigatran from the gastrointestinal tract.
- Surgical hemostasis and blood product replacement: Appropriate surgical procedures should be considered to stop bleeding. Fresh frozen plasma, packed red blood cells, and platelet concentrates may be administered as needed.
- Hemodialysis: Dabigatran can be dialyzed (approximately 60% removed in 2–3 hours), although clinical experience is limited and this is generally reserved for life-threatening situations when idarucizumab is not available.
If you suspect an overdose of dabigatran, seek emergency medical attention immediately. Signs of overdose include excessive or uncontrolled bleeding, severe bruising, blood in urine or stool, vomiting blood, severe nosebleeds, or bleeding gums. A specific reversal agent (idarucizumab/Praxbind) is available in hospitals to rapidly reverse the anticoagulant effect.
What Are the Side Effects of Dabigatran etexilate STADA Nordic?
Like all medicines, dabigatran can cause side effects, although not everybody gets them. The most clinically significant adverse effect of dabigatran is bleeding, which is an inherent consequence of its anticoagulant mechanism of action. Bleeding can occur at any site in the body and can range from minor events (such as bruising or nosebleeds) to serious, life-threatening, or even fatal hemorrhage. The risk of bleeding is influenced by multiple factors, including the dose, patient age, kidney function, concomitant medications, and underlying medical conditions.
In clinical trials, particularly the RE-LY trial which compared dabigatran to warfarin in over 18,000 patients with atrial fibrillation, dabigatran 150 mg twice daily demonstrated a similar rate of major bleeding to warfarin, while dabigatran 110 mg twice daily had a significantly lower rate of major bleeding. However, dabigatran was associated with a higher rate of gastrointestinal bleeding compared to warfarin, particularly in patients aged 75 years and older.
The following side effects have been reported with dabigatran, classified by frequency according to MedDRA convention:
Common
Affects 1 to 10 in every 100 patients
- Decreased hemoglobin (anemia)
- Nosebleeds (epistaxis)
- Gastrointestinal hemorrhage (bleeding from stomach or intestines)
- Abdominal pain or discomfort
- Diarrhea
- Dyspepsia (indigestion, stomach discomfort)
- Nausea
- Skin bleeding (bruising, purpura, hematoma)
- Urogenital bleeding (blood in urine, excessive or irregular menstrual bleeding)
- Bleeding from a wound or following a procedure
Uncommon
Affects 1 to 10 in every 1,000 patients
- Decreased platelet count (thrombocytopenia)
- Allergic reactions (rash, itching, hives, bronchospasm)
- Intracranial hemorrhage (bleeding inside the skull)
- Rectal bleeding
- Hemorrhoidal bleeding
- Gastrointestinal ulceration (stomach or intestinal ulcer)
- Gastroesophagitis (inflammation of the stomach or esophagus)
- Gastroesophageal reflux disease
- Vomiting
- Difficulty swallowing (dysphagia)
- Abnormal liver function tests (elevated transaminases)
- Elevated liver enzymes
- Joint bleeding (hemarthrosis)
- Bleeding from an injection site
- Bleeding from a catheter site
Rare
Affects 1 to 10 in every 10,000 patients
- Anaphylactic reaction (severe allergic reaction)
- Angioedema (swelling of face, lips, tongue, or throat)
- Urticaria (hives)
- Hepatitis (liver inflammation)
- Muscle bleeding
- Surgical site bleeding
Not Known
Frequency cannot be estimated from available data
- Eosinophilic esophagitis (allergic inflammation of the esophagus)
Contact your doctor or go to the nearest emergency department immediately if you experience: bleeding that does not stop, black or bloody stools, vomiting blood or coffee ground-like material, pink or dark red urine, severe headache, confusion, one-sided weakness or visual disturbance (possible signs of intracranial bleeding), severe or unexplained bruising, prolonged or heavy menstrual bleeding, or signs of a severe allergic reaction (difficulty breathing, swelling of face/lips/tongue, severe rash).
It is important to understand that the benefits of dabigatran in preventing stroke and blood clots generally outweigh the risks of side effects for most patients. Your doctor has carefully weighed the benefits and risks when prescribing this medication. Regular follow-up appointments and kidney function monitoring help ensure that the treatment remains appropriate and safe for you. If you experience any side effect that is bothersome, persistent, or concerns you, discuss it with your healthcare provider rather than stopping the medication on your own.
How Should You Store Dabigatran etexilate STADA Nordic?
Proper storage of dabigatran etexilate capsules is essential to maintain their efficacy and safety. Dabigatran etexilate is sensitive to moisture, and exposure to excess humidity can degrade the medication and reduce its effectiveness. Follow these storage guidelines carefully:
- Temperature: Store below 30°C (86°F). Do not freeze. Keep away from direct sunlight and sources of heat.
- Moisture protection: Keep the capsules in their original blister packaging until immediately before use. The blister packaging provides a moisture barrier that protects the capsules. Do not transfer capsules to pill boxes, daily dose organizers, or other containers, as this exposes them to moisture and may compromise their quality.
- Handling: When removing a capsule from the blister, peel back the foil backing rather than pushing the capsule through the foil, as this can damage the capsule. Only remove a capsule from the blister when you are ready to take it.
- Expiry date: Do not use the capsules after the expiry date printed on the blister and carton. The expiry date refers to the last day of that month.
- Keep out of reach: Store all medications out of the sight and reach of children. Accidental ingestion of anticoagulant medication by a child can be extremely dangerous.
- Disposal: Do not throw away unused capsules in household waste or flush them down the toilet. Return unused or expired medication to your local pharmacy for safe disposal in accordance with local regulations. This helps protect the environment.
If you notice any change in the appearance of your capsules (such as discoloration, unusual softness, or visible damage), do not take them and consult your pharmacist. Always check the expiry date before taking any medication.
What Does Dabigatran etexilate STADA Nordic Contain?
Understanding the composition of your medication helps you identify potential allergens and understand the role of each ingredient in the formulation. Dabigatran etexilate STADA Nordic 75 mg hard capsules have the following composition:
Active Substance
Each capsule contains 75 mg of dabigatran etexilate (as dabigatran etexilate mesilate). Dabigatran etexilate mesilate is the salt form used in the formulation for optimal stability and absorption characteristics. Dabigatran etexilate is a prodrug that is rapidly converted to the active form, dabigatran, by esterase enzymes in the plasma and liver after oral absorption. The molecular formula of dabigatran etexilate mesilate is C34H41N7O5·CH4O3S, and its molecular weight is approximately 723.86 g/mol.
Excipients (Inactive Ingredients)
The capsule formulation contains several excipients that serve important pharmaceutical functions:
- Tartaric acid: Creates a local acidic microenvironment in the capsule to ensure consistent and adequate absorption of dabigatran etexilate. This is a critical formulation component, as the absorption of dabigatran etexilate is pH-dependent. The tartaric acid core ensures predictable bioavailability regardless of gastric pH variations.
- Acacia (gum arabic): Used as a binding agent to help maintain the structural integrity of the pellets within the capsule.
- Hypromellose (hydroxypropyl methylcellulose): Functions as a capsule shell material and/or film-forming agent.
- Dimethicone: An anti-foaming agent that prevents air entrapment during manufacturing and aids in the smooth release of the capsule contents.
- Talc: Used as a glidant to improve powder flow during capsule filling and as an anti-adherent.
- Hydroxypropylcellulose: A binding and coating agent used in the pellet formulation.
The hard capsule shell typically contains hypromellose, carrageenan, potassium chloride, titanium dioxide (E171), and yellow iron oxide (E172). Printing ink on the capsule contains shellac, propylene glycol, and iron oxide pigments. If you have known allergies to any of these ingredients, inform your doctor or pharmacist before taking this medication.
The capsule formulation of dabigatran etexilate is specifically designed with tartaric acid-coated pellets to ensure consistent drug absorption. This is why capsules must never be opened, crushed, or chewed. Breaking the capsule would disrupt the carefully engineered tartaric acid microenvironment, leading to a dramatic increase in bioavailability (up to 75% higher than intended) and a significantly elevated risk of serious bleeding. Always swallow the capsules whole with a full glass of water.
Frequently Asked Questions About Dabigatran etexilate STADA Nordic
Dabigatran etexilate STADA Nordic is a generic version of dabigatran etexilate, while Pradaxa is the original brand-name product manufactured by Boehringer Ingelheim. Both contain the same active substance (dabigatran etexilate) and have been demonstrated to be bioequivalent, meaning they deliver the same amount of active drug to the bloodstream at the same rate. Generic medications must meet strict regulatory standards set by the European Medicines Agency (EMA) or equivalent authorities to ensure they are therapeutically equivalent to the originator product. The choice between the brand-name and generic version is primarily based on availability and cost, as they have the same clinical efficacy and safety profile.
Moderate alcohol consumption does not have a direct pharmacokinetic interaction with dabigatran. However, excessive or chronic alcohol use can impair liver function, affect platelet function, and increase the risk of gastrointestinal bleeding – all of which can compound the bleeding risk associated with dabigatran. Additionally, heavy alcohol use increases the risk of falls, which can lead to serious bleeding injuries in anticoagulated patients. It is generally advisable to limit alcohol intake to moderate levels (no more than 1–2 standard drinks per day) and to discuss your alcohol consumption with your doctor.
The duration of dabigatran treatment depends entirely on the reason it was prescribed. For stroke prevention in atrial fibrillation, treatment is typically long-term (often lifelong) unless your doctor determines it should be stopped. For deep vein thrombosis or pulmonary embolism, the initial treatment course is usually at least 3 to 6 months, after which your doctor will reassess whether continued treatment is needed based on your individual risk of recurrence versus bleeding. For prevention of blood clots after hip replacement surgery, treatment typically lasts 28–35 days, and after knee replacement surgery, approximately 10 days. Never stop taking dabigatran without consulting your doctor, as sudden discontinuation can significantly increase the risk of blood clots and stroke.
Always inform your dentist, surgeon, and anesthesiologist that you are taking dabigatran well in advance of any planned procedure. The timing for stopping dabigatran before a procedure depends on your kidney function and the bleeding risk of the procedure. For minor dental procedures (such as a single tooth extraction), dabigatran may not need to be stopped, but your dentist should use local hemostatic measures. For more significant procedures, your doctor will advise you on when to take your last dose – typically 24 to 48 hours before the procedure for patients with normal kidney function, and longer (up to 4–5 days) for patients with impaired kidney function. Do not stop taking dabigatran on your own without medical guidance, and do not restart it after a procedure without your doctor's instructions.
Unlike warfarin, dabigatran does not interact with vitamin K-containing foods, so there are no specific dietary restrictions. You do not need to limit your intake of green leafy vegetables, liver, or other vitamin K-rich foods. Dabigatran can be taken with or without food. However, taking it with food may help reduce gastrointestinal side effects such as indigestion and stomach discomfort. The only dietary consideration is moderate alcohol consumption, as excessive alcohol intake can increase bleeding risk independently. Grapefruit juice does not significantly interact with dabigatran, unlike many other medications.
Yes, switching from warfarin to dabigatran is possible but must be done under medical supervision with careful timing to avoid gaps in anticoagulation or excessive overlap. The standard approach is to stop warfarin and begin dabigatran once the INR (International Normalized Ratio) falls below 2.0. This typically takes 2–3 days after stopping warfarin, depending on individual metabolism. Your doctor will check your INR before starting dabigatran. Conversely, if switching from dabigatran to warfarin, the transition requires overlapping both medications for a period because warfarin takes several days to reach therapeutic effect. Your doctor will manage this transition carefully to ensure you are protected against blood clots throughout the switch.
References
- European Medicines Agency (EMA). Dabigatran etexilate – Summary of Product Characteristics. Last updated 2025. Available from: www.ema.europa.eu
- Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation (RE-LY). N Engl J Med. 2009;361(12):1139-1151. doi:10.1056/NEJMoa0905561
- Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER). N Engl J Med. 2009;361(24):2342-2352. doi:10.1056/NEJMoa0906598
- Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal – Full Cohort Analysis (RE-VERSE AD). N Engl J Med. 2017;377(5):431-441. doi:10.1056/NEJMoa1707278
- European Society of Cardiology (ESC). 2024 ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2024.
- U.S. Food and Drug Administration (FDA). Pradaxa (dabigatran etexilate mesylate) – Prescribing Information. Last updated 2024. Available from: www.fda.gov
- Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23(10):1612-1676.
- World Health Organization (WHO). Model List of Essential Medicines – 23rd List, 2023. Geneva: WHO; 2023.
- Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus Warfarin in Patients with Mechanical Heart Valves (RE-ALIGN). N Engl J Med. 2013;369(13):1206-1214. doi:10.1056/NEJMoa1300615
- International Society on Thrombosis and Haemostasis (ISTH). Guidance on DOAC management in clinical practice. 2024.
Editorial Team
iMedic Medical Editorial Team
Specialists in Hematology, Cardiology, and Clinical Pharmacology
iMedic Medical Review Board
Independent expert panel reviewing all content according to international guidelines (EMA, FDA, ESC, WHO)
All content on iMedic is reviewed by qualified medical professionals following the GRADE evidence framework. We maintain strict editorial independence with no pharmaceutical industry funding or influence. Our evidence standards require Level 1A evidence (systematic reviews and meta-analyses of randomized controlled trials) where available. For more details about our editorial process, visit our Editorial Standards page.